A Study of PRT2527 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 dose-escalation study of PRT2527, a Cyclin-dependent Kinase 9 (CDK9)
inhibitor, in patients with advanced solid tumors. The purpose of this study is to define the
dosing schedule, and maximally tolerated dose to be used in subsequent development of
PRT2527.